TRVN logo

Trevena, Inc.

TRVN

TRVN: Trevena Inc is an American biopharmaceutical company focused on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders.

more

Show TRVN Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of TRVN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by TRVN's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same Jul. 18, 2023
  • Patent Title: 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same Oct. 11, 2022
  • Patent Title: 7-membered aza-heterocyclic containing δ-opioid receptor modulating compounds, methods of using and making the same Jan. 18, 2022
  • Patent Title: Opioid receptor ligands and methods of using and making same Aug. 03, 2021
  • Patent Title: Opioid receptor ligands and methods of using and making same Mar. 17, 2020
  • Patent Title: Methods of treating hyperalgesia Mar. 17, 2020
  • Patent Title: 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same Apr. 02, 2019
  • Patent Title: Opioid receptor ligands and methods of using and making same Dec. 26, 2017
  • Patent Title: Synthesis of beta-arrestin effectors Apr. 04, 2017
  • Patent Title: Beta-arrestin effectors and compositions and methods of use thereof Jan. 03, 2017
  • Patent Title: Crystalline and amorphous forms of a β-arrestin effector Dec. 13, 2016
  • Patent Title: Opioid receptor ligands and methods of using and making same Apr. 12, 2016
  • Patent Title: Opioid receptor ligands and methods of using and making same Jun. 02, 2015
  • Patent Title: Β-arrestin effectors and compositions and methods of use thereof Mar. 31, 2015
  • Patent Title: Beta-arrestin effectors and compositions and methods of use thereof Feb. 03, 2015
  • Patent Title: Opioid receptor ligands and methods of using and making same Sep. 16, 2014
  • Patent Title: Β-arrestin effectors and compositions and methods of use thereof Aug. 19, 2014
  • Patent Title: Β-arrestin effectors and compositions and methods of use thereof Aug. 05, 2014
  • Patent Title: Β-arrestin effectors and compositions and methods of use thereof Jul. 16, 2013
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of TRVN in WallStreetBets Daily Discussion

TRVN News

Recent insights relating to TRVN

CNBC Recommendations

Recent picks made for TRVN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in TRVN

Corporate Flights

Flights by private jets registered to TRVN